Operating Results and Other Financial Information by Segment | Operating results and certain other financial information about the Company’s two reportable segments for the second quarter and first two quarters of fiscal years 2018 and 2017 were as follows: For the Second Quarter of Fiscal Year 2018 MDS ECP Unallocated Eliminations Total (As Restated) (As Restated) Net sales $ 58,353 $ 42,468 $ — $ (3,002 ) $ 97,819 Gross profit 6,960 14,789 — — 21,749 Selling and administrative expenses (incl. depreciation) 5,614 3,570 4,890 — 14,074 Internal research and development expenses — 669 — — 669 Depreciation and amortization 2,247 535 567 — 3,349 Operating income (loss) (208 ) 10,211 (4,890 ) — 5,113 Capital expenditures 2,210 208 226 — 2,644 Total assets at December 31, 2017 $ 145,929 $ 71,410 $ (445 ) $ — $ 216,894 For the Second Quarter of Fiscal Year 2017 MDS ECP Eliminations Total Net sales $ 67,382 $ 32,350 $ — $ (2,333 ) $ 97,399 Gross profit 8,357 7,541 — — 15,898 Selling and administrative expenses (incl. depreciation) 5,561 3,545 3,847 — 12,953 Internal research and development expenses — 533 — — 533 Depreciation and amortization 2,649 585 445 — 3,679 Operating income (loss) 986 3,082 (3,847 ) — 221 Capital expenditures 464 423 564 — 1,451 Total assets at July 2, 2017 $ 142,513 $ 64,694 $ 9,936 $ — $ 217,143 For the First Two Quarters of Fiscal Year 2018 MDS ECP Eliminations Total (As Restated) (As Restated) Net sales $ 113,661 $ 72,867 $ — $ (5,946 ) $ 180,582 Gross profit 12,953 24,720 — — 37,673 Selling and administrative expenses (incl. depreciation) 11,514 7,150 10,615 — 29,279 Internal research and development expenses — 1,241 — — 1,241 Depreciation and amortization 4,575 1,096 1,135 — 6,806 Operating income (loss) (1,693 ) 15,645 (10,615 ) — 3,337 Capital expenditures $ 2,315 $ 395 $ 389 $ — $ 3,099 For the First Two Quarters of Fiscal Year 2017 MDS ECP Eliminations Total Net sales $ 132,384 $ 69,942 $ — $ (4,560 ) $ 197,766 Gross profit 15,651 17,532 — — 33,183 Selling and administrative expenses (incl. depreciation) 11,537 7,369 7,430 — 26,336 Internal research and development expenses — 884 — — 884 Depreciation and amortization 5,325 1,191 883 — 7,399 Operating income (loss) 472 8,511 (7,430 ) — 1,553 Capital expenditures $ 670 $ 758 $ 1,142 $ — $ 2,570 |